Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-(V600) mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzano, José L., Martin-Liberal, Juan, Fernández-Morales, Luis A., Benítez, Gretel, Medina Martínez, Javier, Quindós, María, García-Castaño, Almudena, Fernández, Ovidio, Simo, Rocío V., Majem, Margarita, Bellido, Lorena, Ayala de Miguel, Pablo, Campos, Begoña, Espinosa, Enrique, Macías Cerrolaza, José A., Gil-Arnaiz, Irene, Lorente, David, Rodriguez-Lescure, Alvaro, Perez, Victor N., López Castro, Rafael, Gramaje, María G., Puértolas, Teresa, Rodriguez Moreno, Juan F., Espasa Font, Laia, Belaustegui Ferrández, Guillermo, Cerezuela-Fuentes, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470432/
https://www.ncbi.nlm.nih.gov/pubmed/36988401
http://dx.doi.org/10.1097/CMR.0000000000000888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470432/
https://www.ncbi.nlm.nih.gov/pubmed/36988401
http://dx.doi.org/10.1097/CMR.0000000000000888

Ejemplares similares